Manchester Capital Management LLC Takes $348,000 Position in Collegium Pharmaceutical Inc (COLL)

Manchester Capital Management LLC bought a new position in Collegium Pharmaceutical Inc (NASDAQ:COLL) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 18,857 shares of the specialty pharmaceutical company’s stock, valued at approximately $348,000.

Several other institutional investors and hedge funds have also recently modified their holdings of COLL. Voya Investment Management LLC acquired a new position in Collegium Pharmaceutical during the 2nd quarter valued at approximately $125,000. Benjamin F. Edwards & Company Inc. boosted its position in Collegium Pharmaceutical by 87.5% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 3,500 shares during the period. Nationwide Fund Advisors boosted its position in Collegium Pharmaceutical by 27.8% during the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after purchasing an additional 2,802 shares during the period. Acadian Asset Management LLC acquired a new position in Collegium Pharmaceutical during the 4th quarter valued at approximately $176,000. Finally, JPMorgan Chase & Co. acquired a new position in Collegium Pharmaceutical during the 3rd quarter valued at approximately $192,000. Institutional investors own 82.40% of the company’s stock.

Shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) opened at $25.50 on Thursday. The firm has a market capitalization of $793.54, a price-to-earnings ratio of -8.56 and a beta of 0.80. Collegium Pharmaceutical Inc has a 12 month low of $7.37 and a 12 month high of $26.77.

COLL has been the subject of a number of analyst reports. Janney Montgomery Scott set a $26.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, February 6th. Piper Jaffray Companies set a $33.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Monday, November 13th. Jefferies Group lifted their target price on Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 5th. Finally, Needham & Company LLC lifted their target price on Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, December 5th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $27.17.

In other Collegium Pharmaceutical news, insider Alison B. Fleming sold 4,601 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the sale, the insider now owns 28,513 shares of the company’s stock, valued at approximately $491,849.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Michael Thomas Heffernan sold 20,000 shares of Collegium Pharmaceutical stock in a transaction on Friday, January 19th. The shares were sold at an average price of $22.50, for a total value of $450,000.00. Following the sale, the chairman now directly owns 538,987 shares in the company, valued at approximately $12,127,207.50. The disclosure for this sale can be found here. Insiders have sold a total of 1,055,558 shares of company stock worth $18,570,177 in the last ninety days. 25.76% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Manchester Capital Management LLC Takes $348,000 Position in Collegium Pharmaceutical Inc (COLL)” was reported by Markets Daily and is the property of of Markets Daily. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.themarketsdaily.com/2018/02/15/manchester-capital-management-llc-takes-348000-position-in-collegium-pharmaceutical-inc-coll.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical Inc (NASDAQ:COLL).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply